Annals of Surgical Oncology

, Volume 13, Issue 5, pp 624–634 | Cite as

Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy

  • John H. StewartIV
  • Perry Shen
  • Gregory B. Russell
  • Robert F. Bradley
  • Jonathan C. Hundley
  • Brian L. Loggie
  • Kim R. Geisinger
  • Edward A. Levine



Appendiceal neoplasms frequently present with peritoneal dissemination (PD) and have a clinical course marked by bowel obstruction and subsequent death. Few data have correlated outcome with appendiceal histology after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IPHC). We have reviewed our experience with cytoreductive surgery and IPHC for PD from the appendix.


A total of 110 cases of PD from proven appendiceal neoplasms treated with IPHC were identified from a prospectively managed database. Tumor samples were classified on pathologic review as disseminated peritoneal adenomucinosis (n = 55), peritoneal mucinous carcinomatosis (PMCA) with intermediate features (n = 18), PMCA (n = 29), or high-grade nonmucinous lesions (n = 8). A retrospective review was performed with long-term survival as the primary outcome measure.


A total of 116 IPHCs were performed on 110 patients for appendiceal PD between 1993 and 2004. The 1-, 3-, and 5-year survival rates for all cases were 79.9% ± 4.1%, 59.0% ± 5.7%, and 53.4% ± 6.5%, respectively. When stratified by histology, disseminated peritoneal adenomucinosis and intermediate tumors had better 3-year survival rates (77% ± 7% and 81% ± 10%) than PMCA and high-grade nonmucinous lesions (35% ± 10% and 15% ± 14%; P = .0032 for test of differences between groups). Age at presentation (P = .0134), performance status (P < .0001), time between diagnosis and IPHC (P = .0011), resection status (P = .0044), and length of hyperthermic chemoperfusion (P = .0193) were independently associated with survival.


The data show that long-term survival is anticipated in most patients who are treated with cytoreduction and IPHC for appendiceal PD. The findings presented herein underscore the important prognostic characteristics that predict outcome after IPHC in patients with PD. In all, this work establishes a framework for the consideration of IPHC in future trials for appendiceal PD.


Peritoneal dissemination Disseminated peritoneal adenomucinosis Peritoneal mucinous carcinomatosis Intraperitoneal hyperthermic chemotherapy Mitomycin C Cytoreductive surgery 


  1. 1.
    McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer 2002; 94:3307–12CrossRefPubMedGoogle Scholar
  2. 2.
    Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005; 241:300–8CrossRefPubMedGoogle Scholar
  3. 3.
    Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112–9PubMedGoogle Scholar
  4. 4.
    Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998; 85:1332–9CrossRefPubMedGoogle Scholar
  5. 5.
    Sindelar WF, DeLaney TF, Tochner Z, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Phase I study. Arch Surg 1991; 126:318–24PubMedGoogle Scholar
  6. 6.
    Levine EA. Problems of success and problems of failure: recurrent disease after cytoreductive surgery and intraperitoneal chemoperfusion. Ann Surg Oncol 2004; 11:351–3CrossRefPubMedGoogle Scholar
  7. 7.
    Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138:26–33PubMedGoogle Scholar
  8. 8.
    Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol 1995; 19:1390–408PubMedGoogle Scholar
  9. 9.
    Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89:480–7CrossRefPubMedGoogle Scholar
  10. 10.
    Dedrick RL. Interspecies scaling of regional drug delivery. J Pharm Sci 1986; 75:1047–52PubMedGoogle Scholar
  11. 11.
    Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 1985; 248:F413–24PubMedGoogle Scholar
  12. 12.
    Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994; 46:685–9PubMedGoogle Scholar
  13. 13.
    Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980; 40:567–72PubMedGoogle Scholar
  14. 14.
    Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995; 37:32–8PubMedGoogle Scholar
  15. 15.
    Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982; 42:4265–9PubMedGoogle Scholar
  16. 16.
    Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83:1251–61PubMedGoogle Scholar
  17. 17.
    Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118:547–50PubMedGoogle Scholar
  18. 18.
    Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16:2620–4PubMedGoogle Scholar
  19. 19.
    Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol 1992; 61:221–33PubMedGoogle Scholar
  20. 20.
    Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD, vanderWaal RP, Xu M. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 1998; 3:245–55Google Scholar
  21. 21.
    Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980; 40:1165–8PubMedGoogle Scholar
  22. 22.
    van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 2003; 29:682–8PubMedGoogle Scholar
  23. 23.
    Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004; 5:219–28CrossRefPubMedGoogle Scholar
  24. 24.
    Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. Arch Pathol Lab Med 2002; 126:837–41PubMedGoogle Scholar
  25. 25.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727–31CrossRefPubMedGoogle Scholar
  26. 26.
    Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458–63PubMedGoogle Scholar
  27. 27.
    Elias D, Laurent S, Antoun S, et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy (in French). Gastroenterol Clin Biol 2003; 27:407–12PubMedGoogle Scholar
  28. 28.
    Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11:393–8CrossRefPubMedGoogle Scholar
  29. 29.
    Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 2004; 86:10–5CrossRefPubMedGoogle Scholar
  30. 30.
    Culliford AT, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001; 8:787–95PubMedGoogle Scholar
  31. 31.
    Marcus EA, Weber TK, Rodriguez-Bigas MA, Driscoll D, Meropol NJ, Petrelli NJ. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Invest 1999; 17:249–52PubMedGoogle Scholar
  32. 32.
    Pickhardt PJ, Levy AD, Rohrmann CA Jr, Abbondanzo SL, Kende AI. Non-Hodgkin’s lymphoma of the appendix: clinical and CT findings with pathologic correlation. AJR Am J Roentgenol 2002; 178:1123–7PubMedGoogle Scholar
  33. 33.
    McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27:65–73CrossRefPubMedGoogle Scholar
  34. 34.
    McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10:155–62CrossRefPubMedGoogle Scholar
  35. 35.
    Alexander HR, Mavroukakis SM, Libutti SK, et al. Impact of tumor resection and intraperitoneal chemotherapy on health related quality of life in patients with peritoneal surface malignancies. In: Proceedings of the 57th Annual Society of Surgical Oncology Cancer Symposium. Philadelphia: Lippincott, Williams and Wilkens, 2004Google Scholar
  36. 36.
    Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23:23–9CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2006

Authors and Affiliations

  • John H. StewartIV
    • 1
  • Perry Shen
    • 1
  • Gregory B. Russell
    • 2
  • Robert F. Bradley
    • 3
  • Jonathan C. Hundley
    • 1
  • Brian L. Loggie
    • 4
  • Kim R. Geisinger
    • 3
  • Edward A. Levine
    • 1
  1. 1.Department of General Surgery, Surgical Oncology ServiceWake Forest University School of MedicineWinston-Salem
  2. 2.Department of Public Health Sciences, Section on BiostatisticsWake Forest University School of MedicineWinston-Salem
  3. 3.Pathology DepartmentWake Forest University School of MedicineWinston-Salem
  4. 4.Department of General Surgery, Surgical Oncology SectionCreighton University School of MedicineNebraska

Personalised recommendations